| Trial | control | p<0.05 | harm | NS |
|---|
| A4 (Jais), 2008 | vs control | Freedom from arrhythmia at 12 months per protocol 11.13 [4.27; 29.03] Freedom from arrhythmia at 12 months worst case 11.13 [4.27; 29.03] Freedom from arrhythmia at 12 months ITT 11.13 [4.27; 29.03] | | death 0.00 [0.00; NaN] |
| Wazni , 2005 | vs control | atrial tachyarrhythmia recurrence free survival 4.22 [2.14; 8.32] Freedom from arrhythmia at 12 months per protocol 2.36 [1.50; 3.70] Freedom from arrhythmia at 12 months worst case 2.09 [1.38; 3.17] Freedom from arrhythmia at 12 months ITT 2.17 [1.44; 3.27] | | death NaN [NaN; NaN] adverse clinical event 1.09 [0.30; 4.01] |
| APAF (Pappone), 2006 | vs control | adverse clinical event 0.22 [0.09; 0.55] atrial tachyarrhythmia recurrence free survival 3.86 [2.65; 5.63] Freedom from arrhythmia at 12 months per protocol 2.43 [1.84; 3.21] Freedom from arrhythmia at 12 months worst case 2.43 [1.84; 3.21] Freedom from arrhythmia at 12 months ITT 1.38 [1.22; 1.56] | | death NaN [NaN; NaN] |
| CAFCOAF (Stabile), 2006 | vs control | atrial tachyarrhythmia recurrence free survival 6.43 [2.91; 14.21] Freedom from arrhythmia at 12 months per protocol 9.14 [3.44; 24.23] Freedom from arrhythmia at 12 months worst case 6.09 [2.74; 13.51] Freedom from arrhythmia at 12 months ITT 6.43 [2.91; 14.21] | | death 0.51 [0.05; 5.47] adverse clinical event 0.76 [0.18; 3.27] |
| Krittayaphong, 2003 | vs control | atrial tachyarrhythmia recurrence free survival 2.00 [1.02; 3.91] Freedom from arrhythmia at 12 months ITT 2.00 [1.02; 3.91] | | death NaN [NaN; NaN] adverse clinical event 0.71 [0.29; 1.75] Freedom from arrhythmia at 12 months per protocol 1.96 [1.00; 3.87] Freedom from arrhythmia at 12 months worst case 1.83 [0.92; 3.66] |
| ThermoCool AF, 2008 | vs control | atrial tachyarrhythmia recurrence free survival 3.20 [1.71; 6.00] Symptomatic Atrial Arrhythmia 0.24 [0.15; 0.39] Any Atrial Arrhythmia 0.29 [0.18; 0.46] | | death ∞ [NaN; ∞] |
| Oral, 2006 | vs control | Freedom from arrhythmia at 12 months per protocol 17.03 [5.59; 51.90] Freedom from arrhythmia at 12 months worst case 17.03 [5.59; 51.90] Freedom from arrhythmia at 12 months ITT 1.28 [1.00; 1.62] | | death ∞ [NaN; ∞] |
| Forleo, 2009 | vs control | atrial tachyarrhythmia recurrence free survival 1.87 [1.23; 2.83] Freedom from arrhythmia at 12 months per protocol 1.87 [1.23; 2.83] Freedom from arrhythmia at 12 months worst case 1.87 [1.23; 2.83] Freedom from arrhythmia at 12 months ITT 1.87 [1.23; 2.83] | | death NaN [NaN; NaN] |
| Lakkireddy, 2006 | vs control | | | |
| CABANA, 2018 | vs control | AF recurrence 0.53 [0.46; 0.61] death or CV hospitalization, 0.83 [0.74; 0.93] | | net benefit 0.86 [0.65; 1.14] death 0.85 [0.60; 1.21] death, stroke,stroke, serious bleeding, cardiac arrest 0.86 [0.65; 1.14] |
| STOP-AF, 2010 | vs control | | | |
| Trial | Treatments | Patients | Method |
|---|
| A4 (Jais), 2008 | catheter ablation (n=53) vs. antiarrhythmic drugs (n=59) | patients with paroxysmal AF resistant to at least 1 antiarrhythmic drug. | open Parallel groups Sample size: 53/59 Primary endpoint: none defined FU duration: 12 months |
| Wazni , 2005 | Pulmonary vein isolation (n=32) vs. Flecainide, propafenone, or sotalol; amiodarone if needed (n=35) | Drug-naive monthly symptomatic AF >=3mo | open Parallel groups Sample size: 32/35 Primary endpoint: FU duration: 12 months |
| APAF (Pappone), 2006 | left atrial catheter ablation (n=99) vs. Flecainide acetate, propafenone hydrochloride, or sotalol hydrochloride (n=99) | Drug-refractory paroxysmal AF >=6mo | open Parallel groups Sample size: 99/99 Primary endpoint: FU duration: 12 months |
| CAFCOAF (Stabile), 2006 | left atrial catheter ablation plus amiodarone or other drugs (n=68) vs. Amiodarone or other drugs (n=69) | Drug-refractory or drug-intolerant paroxysmal or persistent AF | open blinded assessment Parallel groups Sample size: 68/69 Primary endpoint: FU duration: 12 months |
| Krittayaphong, 2003 | left atrial catheter ablation (n=15) vs. amiodarone (n=15) | drug-refractory amiodarone-naive paroxysmal or persistent AF >=6mo | open Sample size: 15/15 Primary endpoint: sinus rhythm FU duration: 12 months |
| ThermoCool AF, 2008 | catheter ablation (n=106) vs. antiarrhythmic drug therapy with a class I or III drug (n=61) | patients with AF who were nonresponsive to previous treatment with antiarrhythmic drugs | open Parallel groups Sample size: 106/61 Primary endpoint: treatment failure FU duration: 9 months |
| Oral, 2006 | circumferential pulmonary-vein ablation and amiodarione (n=77) vs. amiodarone and two cardioversions during the first three months alone (n=69) | patients with chronic atrial fibrillation | open Parallel groups Sample size: 77/69 Primary endpoint: FU duration: 12 months |
| Forleo, 2009 | pulmonary vein isolation (n=35) vs. antiarrhythmic drug treatment (n=35) | patients with diabetes mellitus type 2 and paroxysmal or persistent AF | open Parallel groups Sample size: 35/35 Primary endpoint: first AF recurrence FU duration: 12 months |
| Lakkireddy, 2006 | (n=138) vs. (n=139) | | Parallel groups Sample size: 138/139 Primary endpoint: FU duration: |
| CABANA, 2018 | left atrial catheter ablation (n=2204) vs. current state-of-the-art therapy with either rate control or rhythm control drugs (n=0) | patients with untreated or incompletely treated AF | open Parallel groups Sample size: 2204/0 Primary endpoint: all-cause mortality, disabling stroke, serious bleeding, or cardiac arrest FU duration: |
| STOP-AF, 2010 | cryo-balloon catheter for pulmonary vein isolation (n=163) vs. nonfailed antiarrhythmic drugs (n=82) | patients with paroxysmal atrial fibrillation | open Parallel groups Sample size: 163/82 Primary endpoint: treatment succes FU duration: 12 mo |
